biostudies-literatureUnknown18(1)Fruchart JCIn the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent reCardiovascular diabetology71https://www.ebi.ac.uk/biostudies/studies/S-EPMC6549355biostudies-literatureThe selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.PMC6549355Wahli WVrablik MSadikot SOgawa HSantos RDHermans MPLorenzatti AJSu TCCorsini AEckel RHNordestgaard BGCeska RTartar AEzhov MVAguilar-Salinas CKrempf MPradhan AZambon ATenenbaum AAikawa MDespres JPPonte-Negretti CISusekov AVTaskinen MRKodama TSritara PAmarenco PLibby PFarnier MAl Rasadi KBarter PJReiner ZPlutzky JLim SDuriez PTomlinson BRuscica MStock JKGinsberg HNRay KKTybjærg-Hansen AIshibashi SMcPherson RWatts GFRidker PMKarpe FFruchart JCKoenig WPackard CJTokgozoglu LSShimano HYokote KYamashita SValensi PNunez-Cortes JMfalseThe selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent re2019-01-01T00:00:00Z2019 Jun2026-06-19T03:17:25.777Z2019-07-24T07:10:06ZS-EPMC65493553116416510.1186/s12933-019-0864-7